{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T22:47:37Z","timestamp":1789771657062,"version":"4.0.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s40261-024-01394-8","type":"journal-article","created":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T18:02:07Z","timestamp":1728928927000},"page":"761-771","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Differences in the Adverse Event Profiles of Sodium-Glucose Cotransporter 2 Inhibitors used in Patients with Diabetes\u00a0Mellitus and Heart Failure: An Analysis Using the Japanese Adverse Drug Event Report Database"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-6347-7935","authenticated-orcid":false,"given":"Toshiaki","family":"Sakamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1903-9541","authenticated-orcid":false,"given":"Hirotaka","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4588-2500","authenticated-orcid":false,"given":"Junya","family":"Hashizume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1031-2716","authenticated-orcid":false,"given":"Hayato","family":"Akamatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0880-460X","authenticated-orcid":false,"given":"Tomoaki","family":"Akagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukinobu","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Hamano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshito","family":"Zamami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1449-5505","authenticated-orcid":false,"given":"Kaname","family":"Ohyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,14]]},"reference":[{"key":"1394_CR1","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995\u20132008.","journal-title":"N Engl J Med"},{"key":"1394_CR2","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413\u201324.","journal-title":"N Engl J Med"},{"key":"1394_CR3","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, B\u00f6hm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385:1451\u201361.","journal-title":"N Engl J Med"},{"key":"1394_CR4","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387:1089\u201398.","journal-title":"N Engl J Med"},{"key":"1394_CR5","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou F-F, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436\u201346.","journal-title":"N Engl J Med"},{"key":"1394_CR6","doi-asserted-by":"crossref","unstructured":"The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388:117\u201327.","DOI":"10.1056\/NEJMoa2204233"},{"key":"1394_CR7","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/j.cardfail.2021.04.023","volume":"27","author":"H Tsutsui","year":"2021","unstructured":"Tsutsui H, Ide T, Ito H, Kihara Y, Kinugawa K, Kinugawa S, et al. JCS\/JHFS 2021 guideline focused update on diagnosis and treatment of acute and chronic heart failure. J Card Fail. 2021;27:1404\u201344.","journal-title":"J Card Fail"},{"key":"1394_CR8","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599\u2013726.","journal-title":"Eur Heart J"},{"key":"1394_CR9","first-page":"e895","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e895-1032.","journal-title":"Circulation"},{"key":"1394_CR10","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1093\/eurheartj\/ehaa1012","volume":"42","author":"J Bauersachs","year":"2021","unstructured":"Bauersachs J. Heart failure drug treatment: the fantastic four. Eur Heart J. 2021;42:681\u20133.","journal-title":"Eur Heart J"},{"key":"1394_CR11","doi-asserted-by":"crossref","unstructured":"Blau JE, Tella SH, Taylor SI, Rother KI. Ketoacidosis associated with SGLT2 inhibitor treatment: analysis of FAERS data. Diabetes Metab Res Rev. 2017;33.","DOI":"10.1002\/dmrr.2924"},{"key":"1394_CR12","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/phar.1881","volume":"37","author":"KR Burke","year":"2017","unstructured":"Burke KR, Schumacher CA, Harpe SE. SGLT2 inhibitors: a systematic review of diabetic ketoacidosis and related risk factors in the primary literature. Pharmacotherapy. 2017;37:187\u201394.","journal-title":"Pharmacotherapy"},{"key":"1394_CR13","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s00592-022-02015-6","volume":"60","author":"Z He","year":"2023","unstructured":"He Z, Lam K, Zhao W, Yang S, Li Y, Mo J, et al. SGLT-2 inhibitors and euglycemic diabetic ketoacidosis\/diabetic ketoacidosis in FAERS: a pharmacovigilance assessment. Acta Diabetol. 2023;60:401\u201311.","journal-title":"Acta Diabetol"},{"key":"1394_CR14","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1248\/bpb.b22-00034","volume":"45","author":"Y Katsuhara","year":"2022","unstructured":"Katsuhara Y, Ikeda S. Signal detection of acute renal failure following the use of SGLT-2 inhibitors: stratified analysis and time trend analysis in Japan and the United States. Biol Pharm Bull. 2022;45:1077\u201383.","journal-title":"Biol Pharm Bull"},{"key":"1394_CR15","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s40261-020-00925-3","volume":"40","author":"Y Katsuhara","year":"2020","unstructured":"Katsuhara Y, Ogawa T. Acute renal failure, ketoacidosis, and urogenital tract infections with SGLT2 inhibitors: signal detection using a Japanese spontaneous reporting database. Clin Drug Investig. 2020;40:645\u201352.","journal-title":"Clin Drug Investig"},{"key":"1394_CR16","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1002\/jcph.1561","volume":"60","author":"K Sato","year":"2020","unstructured":"Sato K, Mano T, Iwata A, Toda T. Subtype-dependent reporting of stroke with SGLT2 inhibitors: implications from a Japanese pharmacovigilance study. J Clin Pharmacol. 2020;60:629\u201335.","journal-title":"J Clin Pharmacol"},{"key":"1394_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k4365","volume":"363","author":"P Ueda","year":"2018","unstructured":"Ueda P, Svanstr\u00f6m H, Melbye M, Eliasson B, Svensson A-M, Franz\u00e9n S, et al. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ. 2018;363: k4365.","journal-title":"BMJ"},{"key":"1394_CR18","first-page":"849","volume":"27","author":"H Hamano","year":"2019","unstructured":"Hamano H, Mitsui M, Zamami Y, Takechi K, Nimura T, Okada N, et al. Irinotecan-induced neutropenia is reduced by oral alkalization drugs: analysis using retrospective chart reviews and the spontaneous reporting database. Sup Care Cancer Off J Multinatl Assoc Sup Care Cancer. 2019;27:849\u201356.","journal-title":"Sup Care Cancer Off J Multinatl Assoc Sup Care Cancer"},{"key":"1394_CR19","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1111\/cts.13419","volume":"15","author":"H Nawa","year":"2022","unstructured":"Nawa H, Hamano H, Niimura T, Miyata K, Yagi K, Goda M, et al. Evaluation of the potential complication of interstitial lung disease associated with antifibrotic drugs using data from databases reporting spontaneous adverse effects. Clin Transl Sci. 2022;15:2982\u20138.","journal-title":"Clin Transl Sci"},{"key":"1394_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2023.116632","volume":"475","author":"M Neishi","year":"2023","unstructured":"Neishi M, Hamano H, Niimura T, Denda M, Yagi K, Miyata K, et al. Structural characterization of the optical isomers esomeprazole and omeprazole using the JADER and FAERS databases. Toxicol Appl Pharmacol. 2023;475: 116632.","journal-title":"Toxicol Appl Pharmacol"},{"key":"1394_CR21","unstructured":"The Pharmaceuticals and Medical Devices Agency (PMDA) Adverse drug events report dataset download site. http:\/\/www.info.pmda.go.jp\/fukusayoudb\/CsvDownload.jsp. Accessed 15 Jan 2024."},{"key":"1394_CR22","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1111\/jdi.13026","volume":"10","author":"W Ogawa","year":"2019","unstructured":"Ogawa W, Hirota Y. Sodium\u2013glucose cotransporter 2 inhibitor-associated diabetic ketoacidosis in patients with type 1 diabetes: metabolic imbalance as an underlying mechanism. J Diabetes Investig. 2019;10:879\u201382.","journal-title":"J Diabetes Investig"},{"key":"1394_CR23","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/jdi.12401","volume":"7","author":"W Ogawa","year":"2016","unstructured":"Ogawa W, Sakaguchi K. Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors. J Diabetes Investig. 2016;7:135\u20138.","journal-title":"J Diabetes Investig."},{"key":"1394_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2886","volume":"33","author":"H Qiu","year":"2017","unstructured":"Qiu H, Novikov A, Vallon V. Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: Basic mechanisms and therapeutic perspectives. Diabetes Metab Res Rev. 2017;33: e2886.","journal-title":"Diabetes Metab Res Rev"},{"key":"1394_CR25","first-page":"1707","volume":"87","author":"A Tanaka","year":"2023","unstructured":"Tanaka A, Kinugawa K, Kuwahara K, Ito H, Murohara T, Hirata K-I, et al. Recommendation for appropriate use of sodium glucose cotransporter 2 inhibitors in treatment of heart failure. Circ J Off J Jpn Circ Soc. 2023;87:1707\u20139.","journal-title":"Circ J Off J Jpn Circ Soc"},{"key":"1394_CR26","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1001\/jama.1987.03390070069025","volume":"257","author":"RD Abbott","year":"1987","unstructured":"Abbott RD, Donahue RP, MacMahon SW, Reed DM, Yano K. Diabetes and the risk of stroke. The Honolulu Heart Program. JAMA. 1987;257:949\u201352.","journal-title":"JAMA"},{"key":"1394_CR27","doi-asserted-by":"crossref","unstructured":"Emerging Risk Factors Collaboration, Sarwar N, Gao P, Seshasai SRK, Gobin R, Kaptoge S, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet Lond Engl. 2010;375:2215\u201322.","DOI":"10.1016\/S0140-6736(10)60484-9"},{"key":"1394_CR28","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1056\/NEJM199807233390404","volume":"339","author":"SM Haffner","year":"1998","unstructured":"Haffner SM, Lehto S, R\u00f6nnemaa T, Py\u00f6r\u00e4l\u00e4 K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229\u201334.","journal-title":"N Engl J Med"},{"key":"1394_CR29","doi-asserted-by":"publisher","first-page":"2758","DOI":"10.1161\/STROKEAHA.111.621649","volume":"42","author":"Q Jia","year":"2011","unstructured":"Jia Q, Zhao X, Wang C, Wang Y, Yan Y, Li H, et al. Diabetes and poor outcomes within 6 months after acute ischemic stroke: the China National Stroke Registry. Stroke. 2011;42:2758\u201362.","journal-title":"Stroke"},{"key":"1394_CR30","doi-asserted-by":"publisher","first-page":"120","DOI":"10.2337\/diacare.2.2.120","volume":"2","author":"WB Kannel","year":"1979","unstructured":"Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care. 1979;2:120\u20136.","journal-title":"Diabetes Care"},{"key":"1394_CR31","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1056\/NEJMoa1800256","volume":"379","author":"A Rawshani","year":"2018","unstructured":"Rawshani A, Rawshani A, Franz\u00e9n S, Sattar N, Eliasson B, Svensson A-M, et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2018;379:633\u201344.","journal-title":"N Engl J Med"},{"key":"1394_CR32","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","volume":"62","author":"CW Yancy","year":"2013","unstructured":"Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, et al. 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62:e147-239.","journal-title":"J Am Coll Cardiol"},{"key":"1394_CR33","doi-asserted-by":"crossref","unstructured":"Hsiang JC, Wong VW-S. SGLT2 inhibitors in liver patients. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2020;18:2168-2172.e2.","DOI":"10.1016\/j.cgh.2020.05.021"},{"key":"1394_CR34","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S2468-1253(21)00261-2","volume":"7","author":"A Mantovani","year":"2022","unstructured":"Mantovani A, Byrne CD, Targher G. Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review. Lancet Gastroenterol Hepatol. 2022;7:367\u201378.","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"1394_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2020.113249","volume":"291","author":"M Hatano","year":"2020","unstructured":"Hatano M, Kamei H, Shimato A, Yamada S, Iwata N. Trend survey on adverse event profiles of antipsychotic long-acting injections and oral agents using the Japanese adverse drug event report database. Psychiatry Res. 2020;291: 113249.","journal-title":"Psychiatry Res"},{"key":"1394_CR36","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1248\/bpb.b19-00156","volume":"42","author":"G Ando","year":"2019","unstructured":"Ando G, Taguchi K, Enoki Y, Yokoyama Y, Kizu J, Matsumoto K. Evaluation of the expression time of ganciclovir-induced adverse events using JADER and FAERS. Biol Pharm Bull. 2019;42:1799\u2013804.","journal-title":"Biol Pharm Bull"},{"key":"1394_CR37","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s40801-022-00324-4","volume":"9","author":"S Hasegawa","year":"2022","unstructured":"Hasegawa S, Ikesue H, Satake R, Inoue M, Yoshida Y, Tanaka M, et al. Osteonecrosis of the jaw caused by denosumab in treatment-na\u00efve and pre-treatment with zoledronic acid groups: a time-to-onset study using the Japanese adverse drug event report (JADER) database. Drugs Real World Outcomes. 2022;9:659\u201365.","journal-title":"Drugs Real World Outcomes"},{"key":"1394_CR38","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1248\/bpb.b20-00904","volume":"44","author":"T Omoto","year":"2021","unstructured":"Omoto T, Asaka J, Sakai T, Sato F, Goto N, Kudo K. Disproportionality analysis of safety signals for a wide variety of opioid-related adverse events in elderly patients using the Japanese adverse drug event report (JADER) database. Biol Pharm Bull. 2021;44:627\u201334.","journal-title":"Biol Pharm Bull"},{"key":"1394_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0126413","volume":"10","author":"S Matsuda","year":"2015","unstructured":"Matsuda S, Aoki K, Kawamata T, Kimotsuki T, Kobayashi T, Kuriki H, et al. Bias in spontaneous reporting of adverse drug reactions in Japan. PLoS One. 2015;10: e0126413.","journal-title":"PLoS One"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-024-01394-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-024-01394-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-024-01394-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T08:45:08Z","timestamp":1738572308000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-024-01394-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["1394"],"URL":"https:\/\/doi.org\/10.1007\/s40261-024-01394-8","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"9 September 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Toshiaki Sakamoto: Conceptualization, Data curation, Formal analysis, Investigation, Visualization, Writing- original draft. Hirotaka Miyamoto: Methodology, Formal analysis, Validation, Software, Writing - review & editing. Junya Hashizume: Validation, Writing-review & editing. Hayato Akamatsu: Visualization, Writing-review & editing. Tomoaki Akagi: Validation, Writing-review & editing. Yukinobu Kodama: Writing-review & editing. Hirofumi Hamano: Methodology, Software, Writing-review & editing. Yoshito Zamami: Methodology, Software, Writing-review & editing. Kaname Ohyama: Supervision, Writing-review & editing","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All data analyzed in this study are included in this published article. Further inquiries can be directed to the corresponding author.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"The authors declare no conflict of interest.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was exempt from the requirements for ethics approval and informed consent by the Ethics Committee of Nagasaki University because anonymized data obtained from an open-access database were studied.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Statement: During the preparation of this work the authors used DeepL\u00ae for translation from Japanese to English.. After using this tool, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of Generative AI and AI-assisted Technologies in the Writing Process"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}